PENK Methylation Test for Detecting Bladder Cancer

RecruitingOBSERVATIONAL
Enrollment

1,549

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 31, 2024

Conditions
Bladder CancerHematuria; Benign
Interventions
DIAGNOSTIC_TEST

EarlyTect® Bladder Cancer test

A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Korea University Anam Hospital

OTHER

collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Pusan National University Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Ajou University School of Medicine

OTHER

collaborator

Ulsan University Hospital

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Seoul Clinical Laboratories

UNKNOWN

collaborator

Seoul National University Bundang Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT05220189 - PENK Methylation Test for Detecting Bladder Cancer | Biotech Hunter | Biotech Hunter